TY  - JOUR
AU  - Diaz-Villamarin, Xando
AU  - Piñar-Morales, Raquel
AU  - Barrero-Hernandez, Francisco Javier
AU  - Antunez-Rodriguez, Alba
AU  - Cabeza-Barrera, Jose
AU  - Moron-Romero, Rocio
PY  - 2022
DO  - 10.1016/j.biopha.2022.113536
UR  - http://hdl.handle.net/10668/22048
T2  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
AB  - Multiple sclerosis is a chronic inflammatory neurological disease, and siponimod (Mayzent) is the first oral treatment option for adult patients with secondary progressive multiple sclerosis. We performed a systematic review of the pharmacogenetics of...
LA  - en
PB  - Elsevier Masson
KW  - CYP2C9
KW  - Mayzent
KW  - Multiple Sclerosis
KW  - Pharmacogenetics
KW  - Siponimod
KW  - Azetidines
KW  - Benzyl Compounds
KW  - Cytochrome P-450 CYP2C9
KW  - Genotype
KW  - Pharmacogenetics
TI  - Pharmacogenetics of siponimod: A systematic review.
TY  - research article
VL  - 153
ER  -